The Unified Patent Court (UPC) ruled on Tuesday that Amgen’s patent for the cholesterol-lowering drug Repatha is not valid within the European Union. This decision arrives less than a year after the U.S. Supreme Court reached a similar conclusion regarding the drug’s patent status in the United States. The ramifications of such decisions could influence the market dynamics and legal strategies for pharmaceutical patents across both regions.
For further details, the original article is available on Law360.